.jpg "Prof. dr Đorđe Jevtović - Specijalista infektologije")
Specijalista infektologije
Prof. dr Đorđe Jevtović, rođen 1953. godine u Beogradu, lekar-infektolog. Profesor je Medicinskog fakulteta i načelnik centra za HIV na Klinici za infektologiju i tropske bolesti u Beogradu. Dr Jevtović je objavio 208 publikacija kojima su obuhvaćene različite oblasti infektologije.
Prof. dr Đorđe Jevtović je u penziji.
Prof. dr Đorđe Jevtović, rođen 1953. godine u Beogradu, lekar-infektolog. Profesor je Medicinskog fakulteta i načelnik centra za HIV na Klinici za infektologiju i tropske bolesti u Beogradu. Dr Jevtović je objavio 208 publikacija kojima su obuhvaćene različite oblasti infektologije.
Prof. dr Đorđe Jevtović je u penziji.
Osnovne studije.
Profesor.
Načelnik centra za HIV.
Poštovani profesore,
Imam panični strah da ću se zaraziti hivom u nekim nerealnim situacijama, zbog čega uvek izbegavam i najmanji socijalni kontakt (rukovanje i sl.) sa ljudima koji vidno ne vode računa o higijeni ili ljudima čije je ponašanje problematično (poput narkomana).
Na pešačkom prelazu sam se mimoišao sa momkom romske nacionalnosti koji u komšiluku pretura po kontejnerima, i čiji već fizički izgled i ponašanje potencijalno ukazuju na to da je zavisnik. Ako smo prilikom mimoilaženja na ulici ostvarili kratkotrajni kontakt „ruka o ruku“ (da smo se blago očešali jedan o drugog), da li postoji rizik da se zarazim hivom? Momak je imao na laktu neki stari ožiljak koji je ličio kao da je na tom mestu ranije ugašena cigareta, i da je to tako zaraslo, nije izgledalo sveže. Ali sam ja počeo da razmišljam da li je on možda imao na ruci neke kraste i slično, koje nisam primetio, a sa kojima sam imao kontakt kožom svoje ruke prilikom mimoilaženja na ulici. Nisam primetio da mi je na ruci ostao trag bilo kakve krvi i slično, ali ja i pored toga imam paranoju od ovakve situacije i zaraze hivom. Izvinjavam se na verovatno glupom pitanju, znam kako se hiv prenosi, samo što ja ne razmišljam racionalno u ovakvim situacijama. Srdačan pozdrav i unapred hvala na odgovoru.
rizika za sticanje bilo kakve infekcije nije bilo
Postovani da li je pravilno ujutru popijem kafu pa lek delstrigo generalno od pocetka tako radim zanima me da li nece imati efekat na terapiju. Srdacan pozdrav
bez brige
Dobar dan,
Majstor koji mi je popravljao automobil je imao neku posekotinu/ogrebotinu iznad lakta, veličine možda pola centimetara. Mislim da nije aktivno krvarila, ali je delovalo kao da je krv na posekotini/ogrebotini sveža, tj. da je posekotina/ogrebotina skorija.
Ako je on ušao u automobil i seo na mesto vozača da ga isproba i prislonio taj deo ruke na sedište ili dotakao neku drugu površinu u automobilu (volan, menjač), i ako posle pet minuta ja sednem na to vozačevo mesto da vozim i dotaknem te iste površine (dlanovima, prstima, laktom) da li je moguće steći HIV, hepatitis (b, c)? Na prstima imam neke stare ogrebotine koje su zarasle i gde je koža mlada, pa se bojim da sam bio u riziku. Hvala.
nema razloga za brigu-nema rizika
klostridija koja sejavlja po treći put treba mi pomoć za adekvatno lečenje.pored vankomicina i bulardija već tri meseca ,suprug je ležeći pacijent ,fraksiparin 0,3 ujutro, 0,6 uveće,klosridija se vratila po treći put sa krvavim sluzavim stolicama jaki bolovi u stomaku i bolovi u želudcu, Dobili smo preporuku za VSL PROBIOTIK I ZA LACTICHOC LACTOBIANE,Molim Vas za pomoć i mišljenje
postoje preporuke dobre prakse za medikamntozno lečenje recidivantnog pseudomembranoznog kolitisa, koji ne podrazumevaju probiotike, koji se često prepisuju-javite se infektologu u nekoj univerzitetskoj bolnic
iz udžbenika:
Oral vancomycin or oral fidaxomicin
Oral vancomycin or oral fidaxomicin is recommended by the American College of Gastroenterology (1) for the treatment of a primary episode of nonsevere C. difficile–induced diarrhea.
Fidaxomicin 200 mg orally every 12 hours for 10 days is recommended by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) as first-line therapy for C. difficile infection (2). Fidaxomicin decreases the risk of recurrence more than vancomycin. Vancomycin 125 mg orally 4 times a day for 10 days is an alternative (2).
Metronidazole is no longer recommended as first-line therapy for C. difficile–induced diarrhea. However, oral metronidazole can be used if vancomycin or fidaxomicin is not available.
Vancomycin 500 mg orally or by nasogastric tube 4 times a day and metronidazole 500 mg IV every 8 hours are recommended by the ISDA/SHEA for fulminant disease without ileus.
If ileus is present, a retention enema can be given as a dosage of vancomycin 500 mg in 10 mL saline per rectum 4 times a day (1).
If possibly causative antibiotics are being used, they should be stopped as soon as possible, or patients should be switched to an antibiotic regimen less likely to cause C. difficile–induced diarrhea.
Cholestyramine resin, Saccharomyces boulardii yeast, and probiotics have not been proved to be beneficial but are frequently added.
Nitazoxanide appears to be comparable to oral vancomycin but is not commonly used in the United States.
A few patients require total colectomy for cure.
C. difficile–induced diarrhea recurs in 15 to 20% of patients, typically within a few weeks of stopping treatment. Recurrence often results from reinfection (with the same or different strain), but some cases may involve persistent spores from the initial infection. For patients with recurrent infections, the ISDA guidelines suggest fidaxomicin (standard or extended-pulsed regimen) rather than a standard course of vancomycin. Vancomycin in a tapered and pulsed regimen or as a standard course are alternatives for a first recurrence. For patients with multiple recurrences, vancomycin in a tapered and pulsed regimen, vancomycin followed by rifaximin, and fecal microbiota transplantation are options in addition to fidaxomicin (2).
Infusion of donor feces (fecal transplant, usually done via colonoscopy) increases the likelihood of resolution in patients who have frequent recurrences; presumably, the mechanism is restoration of normal fecal microbiota. About 200 to 300 mL of donor feces are used; donors are tested for enteric and systemic pathogens. Feces can be infused using a nasal-duodenal tube, colonoscope, or enema; the optimal method has not been determined.
Oral fecal microbiota transplant capsules and a fecal microbiota suspension for rectal administration are commercially available. They can be given a few days after antibiotic treatment of recurrent C. difficile infection to prevent recurrence.
A human monoclonal antibody, bezlotoxumab 10 mg/kg IV given once, binds to and neutralizes C. difficile toxin B; it can be used for prevention of recurrent C. difficile–induced diarrhea along with standard-of-care treatment in patients who have had a recurrence within the last 6 months.
Infection control measures are vital to reduce the spread of C. difficile among patients and health care workers.
1. Kelly CR, Fischer M, Allegretti JR, et al: ACG Clinical Guidelines: Prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol 116(6):1124–1147, 2021. doi: 10.14309/ajg.0000000000001278. Clarification and additional information. Am J Gastroenterol 117(2):358, 2022.
2. Johnson S, Lavergne V, Skinner AM, et al: Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis 73(5):e1029–e1044, 2021. doi: 10.1093/cid/ciab549
Antibiotic therapy can cause intestinal overgrowth of toxin-secreting C. difficile, resulting in a pseudomembranous colitis that can be severe and difficult to cure.
Cephalosporins (particularly 3rd-generation), penicillins, clindamycin, and fluoroquinolones pose the highest risk.
Diagnose using a stool assay for C. difficile antigen and toxin and sometimes PCR testing for the toxin gene.
Treat with oral fidaxomicin or vancomycin.
Recurrence is common; re-treat with antibiotics, and consider fecal transplantation or bezlotoxumab for refractory recurrences.
The following English-language resources may be useful. Please note that THE MANUAL is not responsible for the content of these resources.
American College of Gastroenterology (ACG): ACG Clinical Guidelines: Prevention, diagnosis, and treatment of Clostridioides difficile infections (2021)
Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): Clinical practice guideline: 2021 Focused update guidelines on management of Clostridioides difficile infection in adults (2021)
Prikazano 191-195 od ukupno 6041 pitanja
Na Stetoskopu lekari i stručni saradnici odgovaraju na najtraženija pitanja na Guglu. Ovo...
Dobro došli! Unesite svoje login podatke
Kontakt je bio 17og marta, radio sam seroloske testove 4te generacije posle 55 dana, 10og jula i poslednji 25og avgusta u izjz, svi su negativni. Molim za mišljenje i savet. Da li uraditi Jos jedan test posle evo skoro 190 dana ili PCR test?
dovoljno je